Ipsen Appoints Gwenan White as Executive Vice President, Communications and Public Affairs
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210119005966/en/
Gwenan White, Executive Vice President, Communications and Public Affairs, Ipsen (Photo: Business Wire)
Ipsen (Euronext: IPN; ADR: IPSEY) announced today the appointment of Gwenan White as Executive Vice President, Communications and Public Affairs, effective March 2021. Based in Boulogne, France, she will be responsible for designing, implementing and managing the communications and public affairs strategy for Ipsen at global level, reporting directly to David Loew, CEO, Ipsen. Gwenan will serve on the Executive Leadership Team.
“Along with the ELT, we are very pleased to welcome Gwenan to Ipsen. She will be critical to the implementation of our new strategy, Focus. Together. For patients & society. Her background in communications and public affairs will help reinforce Ipsen’s position as partner and employer of choice and will contribute to developing the share-of-voice of our innovative medicines. We look forward to working closely with her,” said David Loew, CEO, Ipsen.
“I’m excited to join Ipsen at this key moment,” said Gwenan White. “I look forward to further building Ipsen’s relationships and engagement with institutions and stakeholders worldwide, ensuring the strategic alignment of its communications and boosting the visibility of its brands.”
Prior to joining Ipsen, Gwenan was the Global Head of Pharma Communications and Patient Advocacy at Novartis Pharmaceuticals. Over the course of her career, she has held a variety of roles in public affairs, corporate, science and product communications, patient advocacy and marketing at AbbVie, GSK and Schering Plough.
Gwenan is a graduate of the University of Liverpool in BSc (Hons) Biochemistry in 1990.
She will be based in Boulogne - France.
Ipsen is a global specialty-driven biopharmaceutical group focused on innovation and Specialty Care. The Group develops and commercializes innovative medicines in three key therapeutic areas – Oncology, Neuroscience and Rare Diseases. Its commitment to oncology is exemplified through its growing portfolio of key therapies for prostate cancer, neuroendocrine tumors, renal cell carcinoma and pancreatic cancer. Ipsen also has a well-established Consumer Healthcare business. With total sales over €2.5 billion in 2019, Ipsen sells more than 20 drugs in over 115 countries, with a direct commercial presence in more than 30 countries. Ipsen’s R&D is focused on its innovative and differentiated technological platforms located in the heart of the leading biotechnological and life sciences hubs (Paris-Saclay, France; Oxford, UK; Cambridge, US). The Group has about 5,700 employees worldwide. Ipsen is listed in Paris (Euronext: IPN) and in the United States through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information on Ipsen, visit www.ipsen.com.fr.
Ipsen’s Forward Looking Statement
The forward-looking statements, objectives and targets contained herein are based on the Group’s management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect the Group’s future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words "believes", "anticipates" and "expects" and similar expressions are intended to identify forward-looking statements, including the Group’s expectations regarding future events, including regulatory filings and determinations. Moreover, the targets described in this document were prepared without taking into account external growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by the Group. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact that a promising product in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets, notably for regulatory or competition reasons. The Group must face or might face competition from generic products that might translate into a loss of market share. Furthermore, the Research and Development process involves several stages each of which involves the substantial risk that the Group may fail to achieve its objectives and be forced to abandon its efforts with regards to a product in which it has invested significant sums. Therefore, the Group cannot be certain that favorable results obtained during pre-clinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the product concerned. There can be no guarantees a product will receive the necessary regulatory approvals or that the product will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Other risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the Group's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Group’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. The Group is dependent on prices set for drugs, pricing and reimbursement reforms and is vulnerable to the potential withdrawal of certain drugs from the list of reimbursable products by governments, and the relevant regulatory authorities in its locations. In light of the economic crisis caused by the COVID-19 pandemic, there could be increased pressure on the pharmaceutical industry to lower drug prices. The Group also depends on third parties to develop and market some of its products which could potentially generate substantial royalties; these partners could behave in such ways which could cause damage to the Group’s activities and financial results. The Group cannot be certain that its partners will fulfil their obligations. It might be unable to obtain any benefit from those agreements. A default by any of the Group’s partners could generate lower revenues than expected. Such situations could have a negative impact on the Group’s business, financial position or performance. The Group expressly disclaims any obligation or undertaking to update or revise any forward-looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. The Group’s business is subject to the risk factors outlined in its registration documents filed with the French Autorité des Marchés Financiers. The risks and uncertainties set out are not exhaustive and the reader is advised to refer to the Group’s 2019 Universal Registration Document available on its website www.ipsen.com.
Global Communications Director
+33(0)1 58 33 58 96
Vice President, Investor Relations
+44 (0) 1753 627721
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Global Initiates Expansion Into Bermuda2.3.2021 15:30:00 CET | Press release
Andersen Global establishes a presence in Bermuda through a Collaboration Agreement with Hamilton-based law firm Alexanders, Barristers & Attorneys, adding additional coverage to its global platform. Founded in 2005, Alexanders, Barristers & Attorneys is a law firm with a primary focus on corporate and trust laws. The firm provides services to corporate clients and high net worth individuals, which complements the U.S. member firm’s practice and the global organization’s ability to meet clients’ cross-border needs in Australia, Canada, Africa, the United Kingdom and globally through its member firms and collaborating firms. Additionally, the firm specializes in intellectual property registration and law, investment fund formation and law, insurance company formation and law, and admiralty and maritime law. “Our top priority is delivering best-in-class solutions to our clients locally and abroad, and our ability to do that has been and continues to be a key contributor to our firm’s suc
BORN Expands With Alkeon B2B Market Network Platform Transforming Commercial Models, Starting With the Trade Show Industry2.3.2021 15:12:00 CET | Press release
BORN, announces the expansion of innovative B2B subsidiary Alkeon, the world's first global SaaS market-network combining content, community, and commerce to connect buyers and sellers through a best-in-class platform, powered by machine learning. The 2020 pandemic generated a tremendous and immediate need for companies of all categories to pivot at a moment’s notice, with over 10,000 global trade shows completely upended due to cancellations of physical events. BORN, a purpose driven lifestyle company dedicated to reimagining the discovery, transaction and connection of the B2B and B2C communities, found an opportune moment to quickly scale and enhance their technology solutions. The company formally established Alkeon, an enterprise dedicated to supporting the needs of companies who are adapting to the current and future landscapes and need the right partner to support them through the process. Combining aesthetic and function to create designed technology, Alkeon is a market-network
South Africa and France Lead the Way in Public and Private Sector Gender Diversity, Latest Research by Kearney Reveals2.3.2021 15:00:00 CET | Press release
The latest ‘Gender Equality Report’ from Kearney has revealed progress in the representation of women in both public and private sectors, but the figures still don’t show parity. Ahead of International Women’s Day, the analysis provides insight into the progress of gender diversity in private and public sectors across nine countries – the United States, United Kingdom, Australia, India, France, Spain, Germany, South Africa and Singapore. The annual report revealed that France was number one for representation in the private sector with women comprising nearly 44% (43.8%) of board members on average, however only 2% of these women held top board positions. The UK (36%) and Australia (34%) also scored highly for representation of women on boards. The average for board level representation of women is 29.9% - not even one in three. % Female board level representation by country France 43.8% UK 36.0% Australia 34.0% Germany 32.5% Spain 29.8% US 29.8% South Africa 28.5% Singapore 17.3% Indi
beqom Announces beqom FlexFS, a Compensation Management Solution Dedicated to Financial Services2.3.2021 15:00:00 CET | Press release
beqom, provider of cloud-based compensation management software, today announced the launch of beqom FlexFS, a solution designed specifically for the financial services (FS) industry. “Financial services compensation is unique,” says Vismay Gada, Head of North America and Global Financial Services at beqom. “First there is a broad spectrum of financial services companies—retail banking, investment banking, asset management, hedge funds, insurance, private equity, and so on. That means that rewards and deferred compensation structures have many specialized needs across the industry. And, companies in each segment have to deal with different regulations that impact compensation treatment, which has its own unique challenges. Our FS customers have come to us to help them address complex compensation requirements that are beyond the scope of what their core HR systems can handle.” “We usually see a lot of our FS companies use Excel or Access databases to augment the limitations of core HR
Craig Lipset is Appointed Chairman of the Trialbee Industry Advisory Board2.3.2021 15:00:00 CET | Press release
Trialbee, the leading global data and technology platform provider for patient matching and enrollment in clinical trials, today announced the appointment of Craig Lipset as Chairman of the Trialbee Industry Advisory Board. Craig is a recognized visionary leader who has spent his career dedicated to transforming some of the most challenging issues in clinical research through new innovations. Craig is the former Head of Clinical Innovation and Venture Partner at Pfizer and a distinguished leader at the forefront of innovation in clinical research and medicine development. Most recently Craig cofounded and co-Chairs the Decentralized Trials & Research Alliance (DTRA), which roughly 100 leading life science organizations have joined the first few months since it was established. The core mission of DTRA is making clinical trial participation widely accessible by advancing policies, research practices and new technologies in decentralized clinical research. A significant barrier to patien
Maana and Aramco Trading Company Launch AI Application to Optimize Maritime Fleet and Shipping Operations2.3.2021 15:00:00 CET | Press release
Aramco Trading Company (ATC) and Maana today announced the launch of Fanar, the first Artificial Intelligence (AI)-driven maritime fleet optimization application on Microsoft Azure purpose-built for the oil and gas industry. Fanar combines the expertise of ATC and the Maana Q knowledge technology. It unifies maritime fleet optimization, planning, management and shipment scheduling on a single platform. The application: systematically integrates all data sources, constraints, and business rules automatically optimizes schedules across the fleet with a single click rapidly processes “what if” scenarios for better insights dynamically incorporates historic performance to generate new predictions Fanar has been tested daily by ATC since June 2020. “Collaboration between Maana and Microsoft helps us, through Fanar, to drive down costs,” said Ibrahim Q. Al Buainain, President and CEO of Aramco Trading Company. “Fanar enables us to optimize all local decisions across our maritime shipping and
PierianDx Announces the Appointment of Lindsay Mateo as Chief Business Officer2.3.2021 15:00:00 CET | Press release
PierianDx, the global leader in clinical genomics knowledge, today announced the appointment of Lindsay Mateo as Chief Business Officer, effective immediately. In her new role, Ms. Mateo will reinforce the company’s position as the leading provider of clinical genomics solutions in the fight against cancer and hereditary disease. She will also head the company’s life sciences efforts, establishing key alliances with industry partners and biopharmaceutical companies that will ultimately provide broader access to genomic testing and precision medicine-based treatments for patients. Ms. Mateo is an experienced executive with a history of building world-class teams, devising successful commercial strategies, and building partnerships within the diagnostics industry. Prior to joining PierianDx, she served as Head of Commercial Operations and later as VP, Head of Life Sciences at Tempus. She has also led commercial teams at NAVICAN, an Intermountain Healthcare Company, focused on precision m
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom